GENPHARM CORPORATE OVERVIEW

Transcription

1 GENPHARM CORPORATE OVERVIEW

2 Business Overview Creating specialty pharmaceuticals leadership in MENA Specialty Therapeutic Focus Genpharm is a specialty pharmaceutical marketing and consulting company focused on niche therapeutics and diagnostics for rare disease Specialty Care Women s Health CNS Respiratory Oncology Rare Disease It provides fast and sustainable market access into the MENA (Middle East & North Africa) region to its strategic partners including regulatory and medical Geographical Presence Tunisia Morocco Algeria Libya Egypt Syria Lebanon Iraq Jordan Saudi Arabia Iran Kuwait Bahrain Qatar UAE (Dubai, Headquarter) It provides Business Development and market analysis for companies looking to evaluate the potential of their portfolio in MENA. MENA Yemen It acts as the representative agent for rare disease, biotech and specialty pharma companies looking to enter or to expand in the MENA

3 Company Overview Mission, Vision, Values Our Vision We strive to be the partner of choice for multinational healthcare and pharmaceutical companies expanding into the Middle East and North Africa region. We aim to consistently differentiate ourselves by serving all of our stakeholders through evidence based medicine. Iran Mission Statement To provide healthcare organizations with innovative therapeutic solutions in niche and rare genetic disease areas, market access strategies and sustainable commercial solutions, while improving patient care and quality of life in the Middle East and North Africa. Core Values Patient Care Innovation Accountability Integrity Teamwork We are dedicated to patient care and quality of life We offer unique and sustainable solutions We are committed, reliable and results focused We act honestly, with inclusivity and respect We are positive, professional and transparent 3

4 Experienced Management Team Mr. Karim Smaira Co-founder & CEO 16 years of regional experience in Senior Executive roles in the Pharma industry Launched and managed operations for several Biotech and rare disease products including (go to market strategies & funding) Wide expertise and network in emerging markets, in particular in the Middle East & North Africa Region as well as in South East Europe and Russia. Active member of several industry associations and business councils Member of the Diplomatic Circle in Geneva and Public speaker on industry matters Mr. Kamel Ghammachi Co-founder & Chairman 28 years of regional Pharma experience in Senior Executive roles within MNCs & Distributors Established and Managed several regional offices in MENA Pharmaceutical entrepreneur with several start ups in the region, active member of several industry associations and business councils Honored by Rotary several times as Paul Harris Fellow for meeting outstanding personal, professional standards and charitable work. Several awards recognizing successful businesses in MENA

5 Executive Board Mr. Karim Smaira Mr. Kamel Ghammachi Mr. Elmar Schnee Dr. Samy Ashkar Mr. Rick Pudner CEO 16 years of regional experience in Senior Executive roles Launched and managed operations for several Biotech and rare disease products Wide expertise and network in emerging markets, in particular in the MENA region, South East Europe and Russia. Active member of several industry associations and business councils Chairman 28 years of regional Pharma experience in Senior Executive roles within MNCs & Distributors. Former Managing Director Examon MENA. Former Managing Director Farbro Group. Former General Manager Janssen Cilag ME I. Honored by Rotary several times as Paul Harris Fellow for meeting outstanding personal, professional standards and charitable work. Chairman of Cardiorentis Ltd. Non-executive Director of Jazz Pharmaceuticals Former MD Merck Santé s.a.s, Regular Member of the Executive Board and General Partner of Merck KGaA Held senior positions in Strategy & BD at UCB, Sanofi & others Currently serves on the board of directors of two privately-held life sciences companies. Former CEO of Sterling Natural Science Former CSO Sopherion Therapeutics Former Faculty member Harvard Medical School and The Children s Hospital-Boston. Author of several scientific publications in prestigious journals including Science and JBC Holder of multiple international patents as a result of his scientific research work Former CEO of Emirates NBD; the largest regional bank by Assets Board Member of Galadari Group Board director of Bukhatir Group Former Board Director Emirates Islamic Bank Former Head of Corporate Banking HSBC Middle East; President and CEO of HSBC Korea Director in Emirates Fund Managers (Jersey) Limited, and a founder member of Visa CEMEA Advisory Forum

6 Overview of Current Products & Services Global Pharmaceutical Manufacturers CONSULTANCY Identify business potential Recommend appropriate business & operations models Recommend strategy & organization Formulate adapted market access strategies GENPHARM Services SPECIALTY PHARMA Registration Marketing, Promotion & sales force effectiveness Fast track market penetration through NPS Importation & distribution & Tender participation Medical & PV services Current Partners and Products by Specialities Specialty Care Women s Health CNS Respiratory Oncology Rare Disease Sustainable market access solutions that provide long-term value

7 Company Milestones Apr 2015 Genpharm opens office in Boston Jan 2014 June 2014 Apr 2015 June 2013 Apr 2013 Dec 2012 Oct 2012 Apr 2015 March 2015 Apr 2014 Apr 2013 Feb 2013 Nov 2012 April 2012 Genpharm starts operations

8 Supportive MENA Pharmaceutical Market Middle East continues to outgrow global average IMS Strategic Market Review 2014

9 Targeted and Focused Positioning Genpharm is purposely positioned in the original brands market Business Model Characteristics for different product type Unbranded Generics Branded Generics Unprotected Originals Protected widely RX Niche Specialty Commodity Differentiated High Volume & Low Margin Tight Control of Cost Focus on Supply Chain Purchasing professionals are the key stakeholders Promote price and service Seek scale to gain cost efficiencies and market power Lower Volume & High Margin Emphasis on Quality Focus across a complex set of stakeholders Promote efficacy, safety, tolerability Seek differentiation to drive demand 100% 80% 60% 40% 20% 0% 1% 1% 3% 1% 2% 2% 6% 8% 10% 8% 8% 10% 34% 59% Segment Value by Country 49% 42% 55% 56% 52% 48% 32% 34% 38% 40% UAE KSA Egypt Jordan Morocco Tunisia Original Brands Branded Generics Others Unbranded Generics Segment Volume by Country 2% 1% 2% 3% 2% 2% 100% 12% 12% 16% 18% 17% 29% 80% 60% 57% 61% 60% 54% 61% 52% 40% 20% 30% 27% 22% 27% 18% 18% 0% UAE KSA Egypt Jordan Morocco Tunisia Original Brands Branded Generics Others Unbranded Generics

10 Targeted and Focused Positioning and in the orphan drug market which is consistently outgrowing the non orphan drug market Global Orphan Drug Sales ( bn) Global Orphan Drugs Growth Global Non-Orphan Drugs Growth 22% % % % % 8% % % % 2% 13% 13% % 1% % % 0% % 3% 8% 6% 4% 4% 7% 8% 4% 3% % Source: Evaluate Pharma, April 2013

11 Strong MENA Macro Background MENA population growth to outpace other economic groups 2.5% 2.0% 1.5% 1.0% 0.5% 0.0% 2.0% MENA Countries Population Growth (CAGR ) 0.8% Developing Countries 0.7% Developed Countries Top Countries where Genpharm Operates Qatar Kuwait UAE Oman KSA Bahrain Lebanon Iraq Jordan Egypt GDP per capita, ,653 32,007 18,540 17,931 17,223 7,539 4,610 3,567 2,275 # 76,595 Rank out of 188 countries Population, 2012 (mn) Developing Economies MENA Russia Brazil China India 5,892 10,457 8,305 4,439 1, Developed Economies US Germany UK 37,805 30,611 28, MENA Total Top 5 European Countries North America Global 7,572 Source: IMF Data Note: Developing Countries - China, India, Brazil & Russia; Developed Countries - US, Germany, UK & Canada; North America - US & Canada; KSA stands for Saudi Arabia; Top 5 European Countries UK, Germany, France, Italy, Spain; MENA Countries - Algeria, Bahrain, Djibouti, Egypt, Iran, Iraq, Jordan, Kuwait, Lebanon, Libya, Mauritania, Morocco, Oman, Qatar, Saudi Arabia, Syria, Tunisia, UAE & Yemen; Conversion rate used across slides: 1 US$ =

12 Iraq Qatar Morocco KSA Tunisia Jordan Oman Bahrain UAE Algeria Egypt Lebanon Kuwait MENA China India Russia Brazil US UK Germany Global Strong MENA Macro Background Strong GDP growth provides an upside to healthcare spend Average GDP Growth ( ) 8.0% 7.0% 6.0% 5.0% 4.0% 3.0% 2.0% 1.0% 0.0% 7.2% 6.1% 5.0% 4.2% 4.2% 4.0% 3.8% 3.8% 3.7% 3.6% 3.5% 3.2% 2.8% 4.1% 7.1% 5.8% 3.1% 3.1% 2.9% 1.9% 1.2% 3.8% MENA 1 India China United States Health expenditure per capita: ,294 Health expenditure % of GDP: 4.6% 3.9% 5.2% 17.9% Source: IMF, World Bank Note: (1) MENA comprises Arab World and Iran; Health Expenditure - Data is for 2011, Healthcare expenditure per capita PPP (constant 2005 international $ converted to Euro)

13 Private Some Gvt. Social Sec. Delivering new drugs to MENA markets Genpharm masters product registration and commercialization across MENA Registration: Background and Insights Commercial and Supply chain: Channels and Networks Algeria Jordan KSA Yemen Lebanon Bahrein Kuwait Direct management of a network of distributors chosen over more than 40 years of experience. Egypt Morocco UAE Qatar Major Hospitals and Institutions across MENA. Tunisia Libya Deep expertise and mastering the Name Patient process. Slow Reg. ~3 years Avg. ~15-18months Rapid Reg ~12month Pre-registration market access on the basis of FDA/EMA approvals Strong KOL management in specialty and rare disease areas. Registration friendly environment in GCC- shortened timelines Active role in Pharma forums in the region. Possibility for centralized registration procedure & fast track Pricing Harmonization & International referencing system Established reputation of Genpharm management in the Pharma industry. Government coverage for nationals and insurance privatization trend

14 Holistic Market Approach Physicians Government Programs Scientific Societies Purchasers Patient Associations Health Insurance Distributors Hospital Pharmacies

15 Supportive MENA Pharmaceutical Market Genpharm operates across the entire MENA region and in 8 countries out of the top 10 MEA countries % % 4.8 MEA Pharmaceuticals Sales ( bn) (Top 10 by 2017 sales) % 3.4 5% % % % 1.5-5% KSA Egypt South Africa Algeria Libya Nigeria UAE Morocco 2012 (Genpharm MEA Countries) 2017 (Genpharm MEA Countries) 2012 (Non-Genpharm MEA Countries) 2017 (Non-Genpharm MEA Countries) Source: IMS Health Market Prognosis May Values ex-mfn. at constant exchange rate. Revised Forecast due Sept

16 Targeted and Focused Positioning Genpharm is well positioned in market segments that offer a number of attractive commercial characteristics Genpharm operates in the niche, rare disease/orphan Drug markets where the number of patients and prescribing physicians is limited High Value Products Institutional Customers The rare disease drugs are highly priced due to their research and development cost. Customers are typically government hospitals and similar institutions with a substantial budget for their patients. Genpharm manages all stakeholders including Physicians, Patient groups, Payers and Distributors Need of a highly competent, evidence based selling and promotion approach through a limited number of KAMs/MSLs Limited Number Of Prescribers / Physicians Named Patient Sales [ ] Fast track Registrations Innovative products for unmet medical needs are given fast approval and reimbursement pathway Robust local expertise & knowledge of the local processes Existing network with key decision maker centers and stakeholders markets further helps to access regional markets and help companies with fast track registrations For unmet medical needs and specialty therapeutic, products can be purchased on a Name Patient Sales basis prior to registration. Fast track market access and market penetration. Early sales upside

17 Contact For enquiries and contact: Dubai Biotechnology & Research Park P.O. Box 8145 Dubai, United Arab Emirates Tel: Fax: info@genpharmservices.com Follow us on: Linkedin Twitter